Codifying FDA's plausible mechanism framework is the bet worth watching in PDUFA reauthorization

Mike Davis is calling a specific legislative move during the upcoming Prescription Drug User Fee Act (PDUFA) reauthorization: efforts to codify the FDA’s plausible mechanism framework in statute, paired with guardrails designed to prevent its use where conventional evidence collection remains feasible. The call is dated to the reauthorization cycle now underway, and it will be verifiable when that cycle closes.

The plausible mechanism framework matters because it governs a narrow but high-stakes slice of drug development. The FDA’s own draft guidance on the framework describes how individualized therapies targeting specific genetic conditions with a known biological cause can, under certain circumstances, receive approval on the basis of mechanistic reasoning and nonclinical data rather than traditional randomized clinical evidence. For ultra-rare diseases where assembling a trial population is practically impossible, that pathway is often the only one available.

Davis’s prediction has two moving parts, and both matter. The first is codification: moving the framework from guidance, which the FDA can revise or retract, into statutory or regulatory text, which it cannot change unilaterally. The Penn Leonard Davis Institute of Health Economics has made a similar case in published analysis, arguing that the FDA should move beyond guidance and promulgate formal regulations for the framework, on the grounds that binding rules provide greater certainty for product developers and give the agency clearer enforcement authority. That external pressure gives Davis’s forecast a plausible mechanism of its own.

The second part is the guardrail condition. Davis is explicit that the codification effort would include language limiting the framework’s reach to situations where traditional evidence is genuinely infeasible. That framing reflects a recurring tension in rare disease policy: a pathway built for N-of-1 gene therapies could, without limits, migrate into settings where sponsors simply prefer to avoid the cost and timeline of conventional trials. Guardrails are the legislative attempt to hold that line.

Public reporting from Holland and Knight noted sustained attention throughout 2026 and into 2027 on improving approval pathways for rare and ultra-rare diseases, citing the plausible mechanism draft guidance specifically. Reporting from BioSpace ahead of a recent PDUFA VIII public meeting placed pre-market drug review enhancements among the dominant industry concerns, alongside chemistry, manufacturing, and controls risk. Neither source treats codification of the plausible mechanism framework as settled, but both situate it within an active and crowded reauthorization agenda, which is the context in which Davis’s call sits.

The stakes of the call being right are asymmetric. If codification happens with well-drawn guardrails, developers of individualized rare disease therapies gain the regulatory predictability that guidance alone cannot provide. If codification happens without meaningful guardrails, the framework becomes a tool of convenience rather than necessity, and the FDA’s ability to insist on traditional evidence in appropriate cases weakens. If the effort fails entirely, the framework remains guidance, subject to revision with each administration. Davis’s forecast treats the first scenario as the one advocates will push toward, and the reauthorization calendar makes the next 12 to 18 months the window in which the outcome will be determined.

What the prediction does not resolve is whether the guardrail language, if enacted, will be specific enough to hold. Statutory guardrails in drug policy frequently generate as many interpretive disputes as they settle. The question of what counts as “feasible” to collect traditional evidence is not one that legislation answers cleanly, and the agency will retain significant discretion in applying whatever threshold Congress sets. That ambiguity is not a reason to dismiss the forecast. It is the dimension of it that will matter most if Davis turns out to be right.